# Tejnaksh (NSE: TEJNAKSH) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/TEJNAKSH · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹29 Cr, it ranks 3400th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.

Its return on equity was 4.5% in FY26. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹3 Cr (−20.6% year on year) and net profit ₹0 Cr (−16.7%), on a consolidated basis. Promoters held 73.83% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹29 Cr |
| ROE | 4.5% (FY26) |
| ROCE | 5.9% (FY26) |
| Debt to equity | 0 |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹3 Cr | −20.6% | ₹0 Cr | −16.7% | ₹0.17 |
| Q3 FY26 | ₹3 Cr | −17.9% | ₹0 Cr | −48.2% | ₹0.14 |
| Q2 FY26 | ₹3 Cr | −11.6% | ₹0 Cr | −49.2% | ₹0.15 |
| Q1 FY26 | ₹3 Cr | −15.4% | ₹0 Cr | −65.0% | ₹0.12 |
| Q4 FY25 | ₹3 Cr | +9.9% | ₹0 Cr | −8.7% | ₹0.21 |
| Q3 FY25 | ₹3 Cr | +1.6% | ₹1 Cr | +3.7% | ₹0.38 |
| Q2 FY25 | ₹3 Cr | +9.1% | ₹1 Cr | +6.6% | ₹0.31 |
| Q1 FY25 | ₹3 Cr | +3.0% | ₹1 Cr | +275.0% | ₹0.29 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹9 Cr | ₹3 Cr |
| FY24 | ₹8 Cr | ₹2 Cr |
| FY23 | ₹7 Cr | ₹1 Cr |
| FY22 | ₹8 Cr | ₹3 Cr |
| FY21 | ₹9 Cr | ₹2 Cr |
| FY20 | ₹11 Cr | ₹2 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 73.83%
- Non-institutions: 26.17%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Medi-Caps](https://app.pivotnow.in/stock/MEDICAPQ) | ₹25.50 | ₹32 Cr | — | — |
| [KK Shah Hospita](https://app.pivotnow.in/stock/KKSHL) | — | ₹30 Cr | — | — |
| [Panjon](https://app.pivotnow.in/stock/PANJON) | — | ₹30 Cr | — | — |
| [Soni Medicare](https://app.pivotnow.in/stock/SML) | — | ₹30 Cr | — | — |
| [Chennai Meenaks](https://app.pivotnow.in/stock/CMMHOSP) | — | ₹29 Cr | — | — |
| [SAMSRITA LABS](https://app.pivotnow.in/stock/SAMSRITA) | — | ₹28 Cr | — | — |

## Questions and answers

### What is the market cap of Tejnaksh?

Tejnaksh's market capitalisation is ₹29 Cr (₹29 Cr) at the 22 Oct 2026 close, ranking 3400th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Tejnaksh?

Return on equity was 4.5% in FY26 and return on capital employed was 5.9% in FY26 (consolidated figures).

### Is Tejnaksh a debt-free company?

Tejnaksh is close to debt-free: its debt-to-equity ratio was 0 in FY26.

### What were Tejnaksh's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Tejnaksh reported revenue of ₹3 Cr, −20.6% year on year, and net profit of ₹0 Cr, −16.7% year on year.

### What is the shareholding pattern of Tejnaksh?

As of 30 Jun 2026: promoters 73.83%, non-institutions 26.17%.

### Who are Tejnaksh's competitors?

The listed Pharma & Healthcare companies closest to Tejnaksh by market cap are Medi-Caps, KK Shah Hospita, Panjon, Soni Medicare, Chennai Meenaks and SAMSRITA LABS.

### Is Tejnaksh a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Tejnaksh's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on TEJNAKSH against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.